Phaseline

Companies › Medigen Biotechnology

Medigen Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Allogeneic Magicell-NK
Allogeneic natural killer cells for immunotherapy
–Phase 1Colon Cancer Stage I; Pancreatic Carcinoma Stage IIJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05394714Allogeneic Magicell-NKPhase 1Colon Cancer Stage IOncologyJun 2028
NCT06730009Allogeneic Magicell-NKPhase 1Pancreatic Carcinoma Stage IIOncologyJan 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.